Abstract
An exact classification of precancerous stages of colorectal polyps might improve therapy and patients' outcome. Here we investigate the association between grade of dysplasia and Matrix metalloproteinase-13 (MMP-13) expression in 137 biopsies from patients with cancerous and non-cancerous colorectal adenomas. A reproducible staining procedure for histologic MMP-13 analysis in routinely fixed colorectal biopsy specimens has been established. A newly adopted immunoreactive scoring system for MMP-13 was demonstrated as reliable readout.The strength of the association between pathologic stage and immunoreactive MMP-13 scoring emphasizes its eligibility for diagnosis in precancerous colorectal lesions.
Highlights
Colorectal cancer (CRC) is the third most frequently diagnosed cancer in the world [1]
A high Matrix metalloproteinase-13 (MMP-13) staining score showed a trend towards poorer survival [7] and a high MMP-13 expression level is associated with a high rate of liver metastasis [9]
We demonstrate that MMP-13 expression, quantitatively assessed by a newly adopted immunoreactive score (IRS) and verified by Western blotting, increased with pathological stage of adenoma and carcinoma development
Summary
Colorectal cancer (CRC) is the third most frequently diagnosed cancer in the world [1]. Based on 18 studies, the pooled prevalence of adenomas, colorectal cancer, non-advanced adenomas, and advanced adenomas was 30.2%, 0.3%, 17.7%, and 5.7%, respectively [2]. In a population-based case-control study, the risk of CRC was strongly reduced after colonoscopy for any indication [3]. MMP-7 and MMP-13, which are expressed primarily on the tumor cell surface, are elevated in inflammatory bowel disease [6]. Studies indicate that expression of MMP-13 is closely related to the development and progression of colorectal cancer [7,8,9]. Positive MMP-13 expression was related to bad prognosis and early relapse [7, 10]. MMP-13 could be a useful indicator for tumor behavior and prognosis of CRC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
